Status:
UNKNOWN
Alpha -1- Microglobulin (α1M) as an Early Biomarker in Renal Extrahepatic Manifestations of HCV-infection
Lead Sponsor:
Assiut University
Conditions:
Renal Injury
HCV
Eligibility:
All Genders
18-65 years
Brief Summary
find the role of alpha one microglobulin (as an early renal tubular biomarker) to identify and evaluate the prevalence of early renal manifestations among patients with chronic HCV and compared these ...
Detailed Description
Hepatitis C \[HCV\] infection is known to cause renal manifestations, which are discovered at a late stage when chronic kidney disease (CKD) has already occurred . HCV is both a consequence and cause...
Eligibility Criteria
Inclusion
- Hepatitis C virus (HCV )-positive patients: HCV Antibody and status confirmed by HCV-RNA positive who are either treatment naïve or previously treated.
- 3\. HCV-negative control at outpatients.
Exclusion
- \- 1. HIV-positive patients or Hepatitis B positive (HbsAg) patients or both. 2. Previous renal diseases. 3. Diabetes mellitus, Hypertension, Systemic Lupus erythematosus, Rheumatoid arthritis.
- 4\. patients with Active malignancy. 5. Alcoholics.
Key Trial Info
Start Date :
July 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT05276700
Start Date
July 15 2022
End Date
March 1 2024
Last Update
May 4 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.